PeptideDB

Casein Kinase inhibitor A86 2079069-01-3

Casein Kinase inhibitor A86 2079069-01-3

CAS No.: 2079069-01-3

Casein Kinase inhibitor A86 is a potent and orally bioactive casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibito
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Casein Kinase inhibitor A86 is a potent and orally bioactive casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A86 also inhibits CDK7 (TFIIH) and CDK9 (P-TEFb). Casein Kinase inhibitor A86 can cause apoptosis in leukemia cells and has effective anti-leukemia activity.

Physicochemical Properties


Molecular Formula C18H25FN6
Molecular Weight 344.429706335068
Exact Mass 344.212
CAS # 2079069-01-3
PubChem CID 134812748
Appearance Off-white to light yellow solid powder
LogP 2.4
Hydrogen Bond Donor Count 2
Hydrogen Bond Acceptor Count 6
Rotatable Bond Count 5
Heavy Atom Count 25
Complexity 439
Defined Atom Stereocenter Count 0
SMILES

FC1=CN=C(N=C1C1C=NN(C)C=1CC1CC1)NC1CCC(CC1)N

InChi Key YSPIHUWHLMNFOV-UHFFFAOYSA-N
InChi Code

InChI=1S/C18H25FN6/c1-25-16(8-11-2-3-11)14(9-22-25)17-15(19)10-21-18(24-17)23-13-6-4-12(20)5-7-13/h9-13H,2-8,20H2,1H3,(H,21,23,24)
Chemical Name

4-N-[4-[5-(cyclopropylmethyl)-1-methylpyrazol-4-yl]-5-fluoropyrimidin-2-yl]cyclohexane-1,4-diamine
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets CKIα CDK7 0.31 nM (Kd) CDK9 5.4 nM (Kd)
ln Vitro At 160 nM or less, the casein kinase inhibitor A86 is very effective in causing leukemia cells to undergo apoptosis, primarily due to its ability to stabilize p53[1]. MYC, MDM2, and the anti-apoptotic oncogene MCL1 are all eliminated by the casein kinase inhibitor A86 (0.08-2 μM; 6.5 hours). The Wnt targets AXIN2 and CCND1 (Cyclin D1) are expressed more when the casein kinase inhibitor A86 is used, although the mRNA expression of MYC and MDM2 is significantly reduced[1].
ln Vivo Rapid oral absorption is shown in pharmacokinetic investigations with the Casein Kinase inhibitor A86 at 20 mg/kg, with Tmax values of 0.2-0.5 hours, Cmax values of 1115 ng/mL, T1/2 values of 4.3 hours, and area under the curve (AUC) values of 2606 (ng*hr/mL)[1].
Cell Assay Cell Viability Assay[1]
Cell Types: MV4-11 cells
Tested Concentrations: 0.08 μM, 0.6 μM, 2 μM
Incubation Duration: 6.5 hrs (hours)
Experimental Results: Abolishes the expression of MYC, MDM2, and the anti-apoptotic oncogene MCL1.
References

[1]. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models. Cell. 2018 Sep 20;175(1):171-185.e25.


Solubility Data


Solubility (In Vitro) DMSO : 12.5 mg/mL (36.29 mM)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 1.25 mg/mL (3.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 1.25 mg/mL (3.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 3: ≥ 1.25 mg/mL (3.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.9033 mL 14.5167 mL 29.0335 mL
5 mM 0.5807 mL 2.9033 mL 5.8067 mL
10 mM 0.2903 mL 1.4517 mL 2.9033 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.